You are here: Industry Insights > Pfizer

News List

At second time of asking, Pfizer's Trazimera joins raft of Herceptin biosimilars waiting to launch in US firstwordpharma
March 12, 2019
Pfizer announced that the FDA approved Trazimera (trastuzumab-qyyp) as a biosimilar version of Roche's Herceptin (trastuzumab) for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction a
AbbVie and Pfizer return to the top of pharma's TV spending list for February fiercepharma
March 08, 2019
AbbVie’s Humira is back—at the top of the pharma TV ad spending pile, that is. In February, Humira was the No. 1 spender again, according to data from real-time TV ad tracker iSpot.tv, swapping places with Pfizer’s Xeljanz.
AbbVie and Pfizer return to the top of pharma's TV spending list for February fiercepharma
March 07, 2019
AbbVie’s Humira is back—at the top of the pharma TV ad spending pile, that is. In February, Humira was the No. 1 spender again, according to data from real-time TV ad tracker iSpot.tv, swapping places with Pfizer’s Xeljanz.
AbbVie and Pfizer return to the top of pharma's TV spending list for February fiercepharma
March 07, 2019
AbbVie’s Humira is back—at the top of the pharma TV ad spending pile, that is. In February, Humira was the No. 1 spender again, according to data from real-time TV ad tracker iSpot.tv, swapping places with Pfizer’s Xeljanz.
Merck KGaA, Pfizer added to BioXcel’s pancreatic cancer deal pharmatimes
March 06, 2019
BioXcel Therapeutics has announced the addition of Merck KGaA and Pfizer to clinical collaboration with Nektar Therapeutics, to evaluate a novel triple combination therapy in pancreatic cancer.
EMA follows FDA in putting Pfizer’s Xeljanz under the microscope for safety concerns fiercepharma
March 04, 2019
Xeljanz’s worrisome safety signal has been picked up across the pond. After the FDA issued an alert on the Pfizer blockbuster early this week, the European Medicines Agency said it's kicking off a review of its own.
Pfizer is target of federal civil probe into EpiPen malfunctions fiercepharma
March 04, 2019
Problems for the troubled Pfizer unit that makes EpiPen injectors for Mylan have opened on a new front. The U.S. Attorney for the Southern District of New York is now digging into the issues of why Pfizer continued to produce pens after receiving dozens o
Pfizer braces for work stoppage after announcing it will switch the pensions of Irish holdouts fiercepharma
February 24, 2019
After five years of negotiations, Pfizer has decided it’s time to move employees at plants in Ireland to the same pension plans that the rest of the company’s employees have. That decision comes despite the threat of a work stoppage.
Doctor payments drove scripts for cancer drugs from Pfizer, Novartis and more fiercepharma
February 24, 2019
Critics often target physicians who receive money from pharma, but the exact influence those payments have on prescribing is up for debate. In oncology, at least, it’s not one-off payouts but consistent compensation that's most likely to sway prescribing
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer fiercepharma
February 24, 2019
When it comes to using Xtandi in hormone-sensitive prostate cancer, Pfizer and Astellas are “really excited,” executives have said. And new data shows the partners have reason to be.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page